ServiceNow豪擲77.5億美元收購Armis，企業軟體安全版圖重新洗牌
企業軟體巨頭ServiceNow宣布以77.5億美元現金收購網路安全新創Armis。此舉不僅是ServiceNow今年最大宗的併購案，也預示著企業軟體市場的平台化競爭進入白熱化階段。
企業軟體巨頭的戰爭，已經燒到了網路安全領域。企業級軟體公司ServiceNow宣布，同意以77.5億美元現金收購成立9年的網路安全新創公司Armis。這筆交易不僅讓Armis的估值大幅躍升，也為ServiceNow的併購年畫下一個驚嘆號。
IPO夢想與M&A現實
就在上個月，Armis才剛完成一輪4.35億美元的IPO前募資，當時公司估值為61億美元。其聯合創辦人兼執行長Yevgeny Dibrov曾向媒體表示，公司的目標是在2026年底或2027年上市，並稱IPO是他的「個人夢想」。然而，鑑於IPO市場的不可預測性，以及成功上市的網路安全公司屈指可數，Armis最終選擇以併購（M&A）方式出場，似乎是更務實的選擇。
ServiceNow的擴張版圖
根據ServiceNow的說法，Armis的年度經常性收入（ARR）已達到3.4億美元，年增長率超過50%。Armis主要為財星500大企業和政府提供關鍵基礎設施的安全軟體，將有助於ServiceNow擴展其網路安全產品線。今年對ServiceNow而言是個收購動作頻頻的一年，先前已收購Moveworks（28.5億美元）及Veza（10億美元）。PitchBook數據顯示，Armis已從Sequoia、CapitalG等投資者籌集了總計14.5億美元的風險投資。
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
Enterprise software giant ServiceNow is acquiring cybersecurity startup Armis for $7.75 billion in cash, a move that shelves Armis's IPO plans and signals ServiceNow's aggressive platform strategy.
ServiceNow announces a $7.75 billion cash deal to acquire cybersecurity startup Armis, aiming to build an AI-powered security platform and capitalize on the growing need to protect enterprises from sophisticated AI threats.
Our expert analysis reveals the real reason behind ServiceNow's potential $7B Armis deal. It's not just a cybersecurity play—it's a bid to own the future of enterprise IT.
BioMarin's gene therapy, Roctavian, is moving closer to approval. The company has resubmitted its application to the U.S. FDA and received a positive opinion from the EMA's CHMP for severe hemophilia A.
Enterprise software giant ServiceNow is acquiring cybersecurity startup Armis for $7.75 billion in cash, a move that shelves Armis's IPO plans and signals ServiceNow's aggressive platform strategy.
ServiceNow announces a $7.75 billion cash deal to acquire cybersecurity startup Armis, aiming to build an AI-powered security platform and capitalize on the growing need to protect enterprises from sophisticated AI threats.
Our expert analysis reveals the real reason behind ServiceNow's potential $7B Armis deal. It's not just a cybersecurity play—it's a bid to own the future of enterprise IT.
BioMarin's gene therapy, Roctavian, is moving closer to approval. The company has resubmitted its application to the U.S. FDA and received a positive opinion from the EMA's CHMP for severe hemophilia A.